Table 1.

Combination index analysis to determine the promise of ARV-825 in combinations with other conventional and novel anti-myeloma agents

		ARV-825 (nM)
		1.25	2.5	5	10	20	40
Everolimus	nM
	0.1	1.22	0.70	0.66	0.79	0.75
	0.4	0.54	0.45	0.51	0.60	0.43
	1.6	0.59	0.45	0.51	0.59	0.60
	6.4	0.83	0.60	0.52	0.55	0.53
Dexamethasone	μM
	1.25		0.19
	2.5			0.25
	5				0.37
	10					0.65
	20						1.24
Afuresertib	nM
	20	0.95	1.09	0.83	0.92
	40	1.11	0.79	0.64	0.80
	80	0.68	0.65	0.56	0.76
	160	0.56	0.39	0.46	0.54
Obatoclax	nM
	10	1.10	1.02	0.76	0.92	0.97
	50	0.71	0.63	0.56	0.79	0.62
	250	0.34	0.42	0.52	0.37	0.35
	1250	0.86	0.77	0.77	0.17	0.29
Venetoclax	nM
	10	1.90	1.3	2.39	2.2
	50	0.84	0.96	0.43	1.1
	250	0.59	0.27	1.90	0.9
	1250	0.16	0.07	0.16	0.23